7Baggers

We provide you with 20 years of free, institutional-grade data for VRTX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of VRTX. Explore the full financial landscape of VRTX stock.

Reported DateCIKTickerType
2025-08-061806837VRTX10-QUrl
2025-05-071806837VRTX10-QUrl
2025-02-271806837VRTX10-KUrl
2024-11-061806837VRTX10-QUrl
2024-08-071806837VRTX10-QUrl
2024-05-081806837VRTX10-QUrl
2024-02-291806837VRTX10-KUrl
2023-11-091806837VRTX10-QUrl
2023-08-091806837VRTX10-QUrl
2023-05-101806837VRTX10-QUrl
2023-03-101806837VRTX10-KUrl
2022-11-091806837VRTX10-QUrl
2022-08-091806837VRTX10-QUrl
2022-05-101806837VRTX10-QUrl
2022-03-161806837VRTX10-KUrl
2021-11-121806837VRTX10-QUrl
2021-08-121806837VRTX10-QUrl
2021-05-131806837VRTX10-QUrl
2021-03-151806837VRTX10-KUrl
2020-11-131806837VRTX10-QUrl
2020-09-111806837VRTX10-QUrl
2020-07-021806837VRTXS-1Url

Vertex Pharmaceuticals Incorporated
(NASDAQ:VRTX) 

VRTX stock logo

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regul...

Founded: 1989
Full Time Employees: 3,000
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
The information provided in this report about VRTX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.